Veracyte Inc(VCYT)_个股概要_股票价格_最新资讯_行情走势_历史数据

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VCYT Veracyte Inc

盘前交易 12-15 04:43:40 EST

42.84

+0.62

+1.47%

盘前43.05

+0.21+0.49%

04:41 EST

最高43.41	最低41.55	成交量82.15万
今开42.26	昨收42.22	日振幅4.39%
总市值33.86亿	流通市值33.51亿	总股本7,905万
成交额3,496万	换手率1.05%	流通股本7,823万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"VCYT","market":"US","secType":"STK","nameCN":"Veracyte Inc","latestPrice":42.84,"timestamp":1765573200000,"preClose":42.22,"halted":0,"volume":821525,"hourTrading":{"tag":"盘前","latestPrice":43.05,"preClose":42.84,"latestTime":"04:41 EST","volume":1,"amount":43.05,"timestamp":1765791677224},"delay":0,"floatShares":78227990,"shares":79049173,"eps":0.380419,"marketStatus":"盘前交易","change":0.62,"latestTime":"12-15 04:43:40 EST","open":42.26,"high":43.405,"low":41.55,"amount":34959300.543325,"amplitude":0.043937,"askPrice":53.47,"askSize":100,"bidPrice":35.99,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0.380419,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765809000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1383105600000,"exchange":"NASDAQ","adjPreClose":42.84,"preHourTrading":{"tag":"盘前","latestPrice":43.05,"preClose":42.84,"latestTime":"04:41 EST","volume":1,"amount":43.05,"timestamp":1765791677224},"postHourTrading":{"tag":"盘后","latestPrice":42.84,"preClose":42.84,"latestTime":"18:50 EST","volume":24636,"amount":1055401.99,"timestamp":1765583401446},"volumeRatio":0.8095156543353664,"impliedVol":0.4545,"impliedVolPercentile":0.2731},"requestUrl":"/m/hq/s/VCYT","defaultTab":"news","newsList":[{"id":"2588466030","title":"Morgan Stanley Raises Price Target on Veracyte to $48 From $40, Keeps Underweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2588466030","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588466030?lang=zh_cn&edition=full","pubTime":"2025-12-02 20:07","pubTimestamp":1764677241,"startTime":"0","endTime":"0","summary":"Veracyte (VCYT) has an average rating of overweight and mean price target of $48, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"大摩将Veracyte目标价从40美元上调至48美元，维持跑输大盘评级","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VCYT"],"gpt_icon":0},{"id":"1180399585","title":"异动解读 | 业绩超预期，Veracyte盘中大涨16.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180399585","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180399585?lang=zh_cn&edition=full","pubTime":"2025-11-05 23:05","pubTimestamp":1762355147,"startTime":"0","endTime":"0","summary":"基因组学诊断公司Veracyte Inc今日盘中股价大涨16.18%，延续了昨日夜盘和今日盘前的强劲涨势。这一显著涨幅主要源于公司发布的第三季度财报远超分析师预期，极大地提振了投资者信心。这一亮眼的业绩表现不仅展示了公司的强劲增长势头，还推动股价在夜盘交易中上涨13.98%，并在盘前交易中继续上涨11.16%，最终在盘中交易中达到16.18%的涨幅。作为生物技术领域的领先企业，Veracyte专注于开发和商业化创新的基因组学诊断解决方案。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VCYT"],"gpt_icon":0},{"id":"2581477671","title":"UBS Adjusts Price Target on Veracyte to $48 From $42, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2581477671","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581477671?lang=zh_cn&edition=full","pubTime":"2025-11-05 22:39","pubTimestamp":1762353593,"startTime":"0","endTime":"0","summary":"Veracyte Inc (VCYT) has an average rating of overweight and mean price target of $44.91, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"瑞银将Veracyte目标价从42美元调整至48美元，维持买入评级","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VCYT"],"gpt_icon":0},{"id":"1132350948","title":"异动解读 | 业绩超预期，Veracyte盘前大涨11.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=1132350948","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132350948?lang=zh_cn&edition=full","pubTime":"2025-11-05 18:02","pubTimestamp":1762336967,"startTime":"0","endTime":"0","summary":"基因组学诊断公司Veracyte Inc周三盘前股价大涨11.16%，延续了夜盘交易中的强劲涨势。这一显著涨幅主要源于公司发布的第三季度财报远超分析师预期，极大地提振了投资者信心。作为生物技术领域的领先企业，Veracyte专注于开发和商业化创新的基因组学诊断解决方案。此次超预期的财务业绩凸显了公司在高度竞争的生物技术行业中的竞争优势。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VCYT"],"gpt_icon":0},{"id":"1192308956","title":"异动解读 | 业绩超预期，Veracyte盘前大涨11.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=1192308956","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192308956?lang=zh_cn&edition=full","pubTime":"2025-11-05 18:02","pubTimestamp":1762336964,"startTime":"0","endTime":"0","summary":"基因组学诊断公司Veracyte Inc周三盘前股价大涨11.16%，引发市场广泛关注。这一显著涨幅主要源于公司发布的第三季度财报远超分析师预期。这一亮眼的业绩表现不仅展示了公司的强劲增长势头，还极大地提振了投资者信心，推动股价大幅上涨。作为生物技术领域的领先企业，Veracyte专注于开发和商业化创新的基因组学诊断解决方案。此次超预期的财务业绩凸显了公司在高度竞争的生物技术行业中的竞争优势。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VCYT"],"gpt_icon":0},{"id":"1173779706","title":"异动解读 | 业绩超预期，Veracyte夜盘大涨13.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=1173779706","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173779706?lang=zh_cn&edition=full","pubTime":"2025-11-05 15:38","pubTimestamp":1762328339,"startTime":"0","endTime":"0","summary":"基因组学诊断公司Veracyte Inc周三夜盘交易中股价大涨13.98%，引发市场广泛关注。这一显著涨幅主要源于公司发布的第三季度财报远超分析师预期。这一亮眼的业绩表现不仅展示了公司的强劲增长势头，还极大地提振了投资者信心，推动股价大幅上涨。作为生物技术领域的领先企业，Veracyte专注于开发和商业化创新的基因组学诊断解决方案。此次超预期的财务业绩凸显了公司在高度竞争的生物技术行业中的竞争优势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VCYT"],"gpt_icon":0},{"id":"1164465747","title":"异动解读 | Veracyte盘后大涨5.90%，第三季度业绩超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1164465747","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164465747?lang=zh_cn&edition=full","pubTime":"2025-11-05 05:40","pubTimestamp":1762292437,"startTime":"0","endTime":"0","summary":"周二盘后，Veracyte Inc（VCYT）股价大涨5.90%，引发投资者关注。\n\n据报道，Veracyte公布的第三季度财报显示，公司净收入达到1.319亿美元，远超分析师预期的1.246亿美元。这一亮眼的业绩表现成为推动股价上涨的主要动力。\n\nVeracyte是一家专注于基因组学诊断的生物技术公司。此次超预期的财务业绩不仅展示了公司的强劲增长势头，还增强了投资者对其未来发展前景的信心。在当前生物技术行业竞争激烈的环境下，Veracyte的出色表现无疑为其在市场中赢得了更多关注和支持。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VCYT"],"gpt_icon":0},{"id":"1165563605","title":"Veracyte第三季度收入1.319亿美元 超出IBES预估的1.246亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1165563605","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165563605?lang=zh_cn&edition=full","pubTime":"2025-11-05 05:25","pubTimestamp":1762291543,"startTime":"0","endTime":"0","summary":"11月4日消息 - Veracyte第三季度净收入为1910万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VCYT"],"gpt_icon":0},{"id":"2576639856","title":"Canaccord Genuity Initiates Coverage on Veracyte With Hold Rating, $40 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2576639856","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576639856?lang=zh_cn&edition=full","pubTime":"2025-10-20 19:36","pubTimestamp":1760960196,"startTime":"0","endTime":"0","summary":"Veracyte Inc (VCYT) has an average rating of overweight and mean price target of $42.18, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"Canaccord Genuity首次对Veracyte给予持有评级，目标价40美元","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VCYT"],"gpt_icon":0},{"id":"2572351459","title":"Veracyte, Inc.盘中异动 下午盘快速上涨5.01%报36.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2572351459","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2572351459?lang=zh_cn&edition=full","pubTime":"2025-10-02 02:34","pubTimestamp":1759343658,"startTime":"0","endTime":"0","summary":"北京时间2025年10月02日02时34分，Veracyte, Inc.股票出现波动，股价大幅上涨5.01%。截至发稿，该股报36.05美元/股，成交量53.6235万股，换手率0.68%，振幅5.20%。Veracyte, Inc.股票所在的生命科学行业中，整体涨幅为4.59%。Veracyte, Inc.公司简介：Veracyte Inc 是一家基因组诊断公司。此外，其 Percepta 鼻拭子测试正在 CLIA 实验室进行，以支持临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251002023418971c2738&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VCYT","BK4139"],"gpt_icon":0},{"id":"1109356611","title":"Veracyte宣布其Decipher生物标记物可预测激素疗法对复发性前列腺癌男性患者的治疗效果","url":"https://stock-news.laohu8.com/highlight/detail?id=1109356611","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109356611?lang=zh_cn&edition=full","pubTime":"2025-09-29 04:00","pubTimestamp":1759089618,"startTime":"0","endTime":"0","summary":"Veracyte宣布其Decipher生物标记物可预测激素疗法对复发性前列腺癌男性患者的治疗效果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VCYT","BK4139"],"gpt_icon":0},{"id":"2570069604","title":"Veracyte, Inc.盘中异动 股价大跌5.21%报32.37美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2570069604","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570069604?lang=zh_cn&edition=full","pubTime":"2025-09-25 02:20","pubTimestamp":1758738025,"startTime":"0","endTime":"0","summary":"北京时间2025年09月25日02时20分，Veracyte, Inc.股票出现波动，股价大幅下挫5.21%。截至发稿，该股报32.37美元/股，成交量32.1406万股，换手率0.41%，振幅4.81%。Veracyte, Inc.股票所在的生命科学行业中，整体跌幅为1.46%。Veracyte, Inc.公司简介：Veracyte Inc 是一家基因组诊断公司。此外，其 Percepta 鼻拭子测试正在 CLIA 实验室进行，以支持临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250925022025a4419e3b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VCYT"],"gpt_icon":0},{"id":"1191506970","title":"Veracyte宣布预测复发性前列腺癌男性患者激素治疗获益的生物标志物首个前瞻性验证数据将在ASTRO 2025大会上发布","url":"https://stock-news.laohu8.com/highlight/detail?id=1191506970","media":"美股速递","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191506970?lang=zh_cn&edition=full","pubTime":"2025-09-24 21:01","pubTimestamp":1758718884,"startTime":"0","endTime":"0","summary":"Veracyte公司宣布，其用于预测复发性前列腺癌男性患者激素治疗获益的生物标志物的首个前瞻性验证数据将在ASTRO 2025大会上进行展示。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VCYT"],"gpt_icon":0},{"id":"2562734808","title":"Veracyte Completes Enrollment for Clinical Utility Trial to Evaluate Nasal Swab Lung Cancer Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2562734808","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562734808?lang=zh_cn&edition=full","pubTime":"2025-08-26 21:29","pubTimestamp":1756214949,"startTime":"0","endTime":"0","summary":"Veracyte  said Tuesday that it has reached its target enrollment for a clinical utility trial evaluating its Percepta Nasal Swab test.The cancer diagnostics company said the trial has now enrolled 2,400 patients at more than 90 academic and community centers across the US.The test is used to assess molecular changes associated with lung cancer risk in patients with lung nodules and a history of smoking, the company said.Shares of Veracyte were up 6% in recent Tuesday premarket activity.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"Veracyte完成临床效用试验的招募，以评估鼻拭子肺癌测试","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","VCYT"],"gpt_icon":0},{"id":"1109916390","title":"Veracyte完成Percepta鼻拭子肺癌检测夜莺临床实用性试验的患者招募","url":"https://stock-news.laohu8.com/highlight/detail?id=1109916390","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109916390?lang=zh_cn&edition=full","pubTime":"2025-08-26 20:31","pubTimestamp":1756211482,"startTime":"0","endTime":"0","summary":"Veracyte完成Percepta鼻拭子肺癌检测夜莺临床实用性试验的患者招募","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VCYT","BK4139"],"gpt_icon":0},{"id":"1123910413","title":"异动解读 | Veracyte盘中大涨8.47%，二季度业绩超预期并上调全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1123910413","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123910413?lang=zh_cn&edition=full","pubTime":"2025-08-07 21:46","pubTimestamp":1754574394,"startTime":"0","endTime":"0","summary":"今日盘中，Veracyte Inc股价大涨8.47%，引发市场关注。这一强劲涨势主要源于公司发布的2025年第二季度财报超出市场预期，并上调了全年业绩指引。值得注意的是，尽管产品收入略有下滑，但生物制药及其他收入增长21%，达到430万美元。展望未来，Veracyte上调了2025年全年测试收入指引至4.77亿至4.83亿美元，同比增长14%至15%。Veracyte首席执行官Marc Stapley表示，对公司实现可持续长期营收增长的能力充满信心，这得益于公司差异化的平台和不断增长的临床证据支持。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VCYT"],"gpt_icon":1},{"id":"1121210043","title":"异动解读 | Veracyte季度业绩超预期，股价盘中大涨8.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=1121210043","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121210043?lang=zh_cn&edition=full","pubTime":"2025-08-07 21:46","pubTimestamp":1754574391,"startTime":"0","endTime":"0","summary":"医疗诊断公司Veracyte Inc周四盘中股价大涨8.47%，引发投资者关注。这一显著涨幅主要源于公司发布的强劲第二季度财报以及上调的全年业绩指引。根据公司最新公布的财务报告，Veracyte第二季度总营收达到1.302亿美元，同比增长14%，超出分析师预期的1.207亿美元。同时，公司首次发布2025年全年总营收指引，预计为4.96亿至5.04亿美元，显示11%至13%的同比增长。这些积极的财务指标和乐观的业绩展望无疑增强了投资者对Veracyte未来增长潜力的信心，推动了股价的大幅上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VCYT"],"gpt_icon":1},{"id":"2557561678","title":"Veracyte, Inc.盘中异动 早盘快速上涨7.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2557561678","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557561678?lang=zh_cn&edition=full","pubTime":"2025-08-07 21:31","pubTimestamp":1754573474,"startTime":"0","endTime":"0","summary":"北京时间2025年08月07日21时31分，Veracyte, Inc.股票出现波动，股价急速上涨7.80%。Veracyte, Inc.股票所在的生命科学行业中，整体涨幅为0.93%。其相关个股中，Guardant Health, Inc.、燃石医学、Veracyte, Inc.涨幅较大，Biodesix, Inc.、Applied Dna Sciences, Inc.、Check-Cap Ltd.较为活跃，换手率分别为0.81%、0.72%、0.37%，振幅较大的相关个股有Inotiv, Inc.、Guardant Health, Inc.、Biodesix, Inc.，振幅分别为9.59%、3.23%、2.46%。Veracyte, Inc.公司简介：Veracyte Inc 是一家基因组诊断公司。此外，其 Percepta 鼻拭子测试正在 CLIA 实验室进行，以支持临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807213114a47b2450&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","VCYT","BDSX","BK4196"],"gpt_icon":0},{"id":"2557029993","title":"Veracyte Q2 2025 Adj. EPS $0.44 Beats $0.25 Estimate, Sales $130.164M Beat $121.173M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2557029993","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557029993?lang=zh_cn&edition=full","pubTime":"2025-08-07 04:12","pubTimestamp":1754511163,"startTime":"0","endTime":"0","summary":"Veracyte Q2 2025 Adj. EPS $0.44 Beats $0.25 Estimate, Sales $130.164M Beat $121.173M Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"Veracyte 2025年第二季度调整后每股收益0.44美元，超出预期0.25美元，销售额13016.4万美元，超出预期12117.3万美元","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/46925086/veracyte-q2-2025-adj-eps-0-44-beats-0-25-estimate-sales-130-164m-beat-121-173m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Veracyte Q2 2025 Adj. EPS $0.44 Beats $0.25 Estimate, Sales $130.164M Beat $121.173M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VCYT"],"gpt_icon":0},{"id":"2554295798","title":"Sector Update: Health Care Stocks Edge Higher Premarket Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2554295798","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554295798?lang=zh_cn&edition=full","pubTime":"2025-07-25 21:30","pubTimestamp":1753450224,"startTime":"0","endTime":"0","summary":"Health care stocks were edging higher premarket Friday with the iShares Biotechnology ETF  slightly advancing 0.1% and the Health Care Select Sector SPDR Fund  up 0.2% recently.Centene  stock was more than 2% higher even after the company reported that it swung to a Q2 adjusted loss.Veracyte  is set to join the S&P SmallCap 600, effective Tuesday, to replace Triumph Group , S&P Dow Jones Indices said. Shares of Veracyte were up more than 8% premarket.Sarepta Therapeutics  shares were more than 13% lower after Europe's drug regulator recommended the refusal of marketing authorization for the company's Duchenne muscular dystrophy drug Elevidys.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"行业更新：医疗保健股周五盘前小幅走高","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B66KJ199.SGD","LU0477156953.USD","LU1201861249.SGD","BK4139","LU1699723380.USD","LU2362541273.HKD","LU0130103400.USD","IE00BJT1NW94.SGD","BK4588","IE00B2B36J28.USD","LU0477156797.USD","SRPT","IE0009355771.USD","BK4187","LU0130102774.USD","VCYT","BK4581","IE00B19Z4B17.USD","IE0034235188.USD","LU0648000940.SGD","XLV","TGI","LU2362540622.SGD","LU0130518102.USD","IE0031619046.USD","CNC","LU1989771016.USD","IBB","LU0980610538.SGD","IE00BJJMRZ35.SGD","LU0648001328.SGD","LU1291159041.SGD","IE0002141913.USD","LU1201861165.SGD","IE00B7SZL793.SGD","LU0130517989.USD","BK4154","LU2362541513.USD","IE00BFTCPJ56.SGD","BK4585"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.veracyte.com","stockEarnings":[{"period":"1week","weight":-0.0397},{"period":"1month","weight":0.0128},{"period":"3month","weight":0.3873},{"period":"6month","weight":0.6203},{"period":"1year","weight":-0.0351},{"period":"ytd","weight":0.0818}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Veracyte, Inc.作为Calderome控股公司于2006年8月15日在特拉华州注册成立。 直到2008年初，Calderome一直运营作为一个创业园。2008年3月4日，公司更名为Veracyte有限公司。Veracyte是一家首创分子细胞学领域的诊断学公司，以改善患者的结果和降低医疗费用。公司专门针对经常需要侵入性程序的疾病达到准确的诊断——在疾病上，许多健康的患者进行代价高昂的干预，最终被证明是不必要的。公司由收集在门诊细胞学标本得出临床可操作的基因组信息，在较早阶段提高了病人护理的诊断的准确度。公司的第一个商业解决方案——Afirma甲状腺FNA 分析，包括作为其核心的基因表达分类（GEC）。GEC帮助医生通过采用专有的142个基因标记减少不必要的手术的数量，以术前确定是否先前由细胞病理学分类为不确定的甲状腺结节可以被重新分类为良性。公司的业务总部设在加利福尼亚州的南旧金山市和得克萨斯州的奥斯汀市而且它在一个部门运作。","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.006723},{"month":2,"riseRate":0.5,"avgChangeRate":-0.011384},{"month":3,"riseRate":0.25,"avgChangeRate":-0.027945},{"month":4,"riseRate":0.5,"avgChangeRate":-0.024173},{"month":5,"riseRate":0.416667,"avgChangeRate":0.011733},{"month":6,"riseRate":0.833333,"avgChangeRate":0.070248},{"month":7,"riseRate":0.583333,"avgChangeRate":0.070508},{"month":8,"riseRate":0.5,"avgChangeRate":0.025703},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.069317},{"month":10,"riseRate":0.5,"avgChangeRate":0.077846},{"month":11,"riseRate":0.692308,"avgChangeRate":0.116902},{"month":12,"riseRate":0.461538,"avgChangeRate":0.017355}],"exchange":"NASDAQ","name":"Veracyte Inc","nameEN":"Veracyte"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Veracyte Inc(VCYT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Veracyte Inc(VCYT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Veracyte Inc,VCYT,Veracyte Inc股票,Veracyte Inc股票老虎,Veracyte Inc股票老虎国际,Veracyte Inc行情,Veracyte Inc股票行情,Veracyte Inc股价,Veracyte Inc股市,Veracyte Inc股票价格,Veracyte Inc股票交易,Veracyte Inc股票购买,Veracyte Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Veracyte Inc(VCYT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Veracyte Inc(VCYT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}

公司概况